Home > In process > Executive anosognosia in progressive supranuclear palsy versus Parkinson's disease. > print

001     285265
005     20260219163204.0
024 7 _ |a 10.3389/fneur.2026.1744979
|2 doi
024 7 _ |a pmid:41704890
|2 pmid
024 7 _ |a pmc:PMC12907162
|2 pmc
037 _ _ |a DZNE-2026-00207
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ye, L.
|b 0
245 _ _ |a Executive anosognosia in progressive supranuclear palsy versus Parkinson's disease.
260 _ _ |a Lausanne
|c 2026
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771515012_3451
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Executive function deficits are common among patients with Parkinson's disease (PD) and progressive supranuclear palsy (PSP). Executive function refers to higher-order cognitive processes thought to involve fronto-striatal circuits. Some patients with executive deficits may be unable to recognize or report them, a condition we refer to as executive anosognosia.To conduct a comparative analysis of executive anosognosia in patients diagnosed with PSP and PD.We compared an objective neuropsychological assessment (ONA) of composite executive function (ONA-CEF), which includes semantic and phonemic verbal fluency, as well as two sub-scores from the Wisconsin Card Sorting Test, with patient- and informant-reported rating scales. We used the Dysexecutive Questionnaire Revised (DEX-R) to evaluate near-transfer executive complaints and the Aachen Activity and Participation Index: Cognition and Participation (AAPI-CP) composite to evaluate far-transfer cognitive and social difficulties. Discrepancy indices were calculated for patients and informants (ONA-CEF minus DEX-R and ONA-CEF minus AAPI-CP).PSP patients had significantly larger negative discrepancies than PD patients, indicating stronger executive anosognosia. Although informant reports reduced these discrepancies, significant underreporting persisted in PSP informants. Correlational analyses revealed that patient-reported DEX-R difficulties were strongly correlated with depressive symptoms (r ≈ 0.65) but not with objective executive performance (r ≈ 0.00).Executive anosognosia is a marker of PSP, highlighting the need for objective neuropsychological assessments in clinical trials. PSP patients' reports of executive dysfunction are more associated with mood than actual impairment, which challenges the validity of patient-reported outcomes in PSP and related neurological diseases.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a anosognosia
|2 Other
650 _ 7 |a executive function
|2 Other
650 _ 7 |a patient-reported outcome measures
|2 Other
650 _ 7 |a progressive supranuclear palsy
|2 Other
700 1 _ |a Seidler, L.
|b 1
700 1 _ |a Chemodanow, D.
|b 2
700 1 _ |a Respondek, G.
|b 3
700 1 _ |a Niesmann, C.
|b 4
700 1 _ |a Wilkens, I.
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Klietz, M.
|b 6
700 1 _ |a Höglinger, G. U.
|0 P:(DE-2719)2811373
|b 7
|u dzne
700 1 _ |a Kopp, B.
|b 8
773 _ _ |a 10.3389/fneur.2026.1744979
|g Vol. 17, p. 1744979
|0 PERI:(DE-600)2564214-5
|p 1744979
|t Frontiers in neurology
|v 17
|y 2026
|x 1664-2295
856 4 _ |u https://pub.dzne.de/record/285265/files/DZNE-2026-00207.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285265/files/DZNE-2026-00207.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT NEUROL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-11T07:34:54Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-11T07:34:54Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-01-11T07:34:54Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-01-11T07:34:54Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21